Medindia » Health Press Releases A-Z

DelMar Pharmaceuticals Reports Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083 as First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)

53% of assessed patients have achieved a complete response; 41% have achieved stable disease